N/A
Completed N=238
Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov NCT01229462 ↗Enrolled (actual)
238
Serious AEs
0.9%
Results posted
Sep 2012
Primary outcomePrimary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4 — 25.07; 24.53; -6.21; -5.70 mm Hg
Summary
This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye at Week 4 |
25.07; 24.53; -6.21; -5.70 | — |
Eligibility Criteria
Inclusion Criteria
- Open-angle glaucoma or ocular hypertension in at least one eye that is not responsive to topical beta blockers
- No anticipated wearing of contact lenses during study
Exclusion Criteria
- Active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
- Any intraocular surgery or laser (eg, cataract surgery or Lasik) within 3 months
- Required regular use of other ocular medications except for occasional use of artificial tears
Data sourced from ClinicalTrials.gov (NCT01229462). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.